Theralase Technologies Inc. (TLT) | WebDisclosure

Switch to English

8302	Sociétés
115129	Mots-clés
55450	Articles
62533	Communiqués

Accueil
Sociétés
Theralase Technologies Inc.

COMMUNIQUÉ DE PRESSE

publié le 08/02/2024 à 13:00, il y a 9 mois 13 jours

Dr. Michael Jewett Joins Theralase(R) to Help Complete Enrollment in the Phase II Non-Muscle Invasive Bladder Cancer Clinical Study
Theralase® Technologies Inc. announces the addition of Dr. Michael Jewett as an independent consultant to assist in completing enrollment of patients in the Phase II NMIBC CIS clinical study. Dr. Jewett's expertise will help achieve regulatory approval

Clinical Study Regulatory Approval Theralase® Technologies Inc. Dr. Michael Jewett Enrollment
COMMUNIQUÉ DE PRESSE

publié le 05/02/2024 à 22:35, il y a 9 mois 16 jours

Theralase(R) Closes $CAN 1.2 Million Non-Brokered Private Placement
Theralase Technologies Inc. has closed a non-brokered private placement offering of units, raising approximately $CAN 1,200,000 for cancer research and development. The company plans to use the funds for clinical study, preclinical research, and general corporate purposes

Pharmaceutical Company Private Placement Offering Theralase Technologies Inc. Clinical Study Cancer Research
COMMUNIQUÉ DE PRESSE

publié le 15/01/2024 à 13:00, il y a 10 mois 6 jours

Theralase(R) Provides Update on Phase II Bladder Cancer Clinical Study
Theralase Technologies Inc. provides an update on its Phase II Non-Muscle Invasive Bladder Cancer clinical study, demonstrating favorable interim clinical data that exceeds the International Bladder Cancer Group's guidelines. With 63 patients treated to date, the study shows promising results, potentially leading to Break Through Designation and Accelerated Approval. The Company plans to complete enrollment and delivery of the primary Study II Treatment for all patients in 2024, with potential Health Canada and FDA approval expected by 2026 / 2027.

Theralase Technologies Inc. Bladder Cancer Clinical Study Break Through Designation Accelerated Approval Health Canada And FDA Approval
COMMUNIQUÉ DE PRESSE

publié le 30/11/2023 à 00:30, il y a 11 mois 22 jours

Theralase Release’s 3Q2023 Interim Financial Statements
Theralase Technologies Inc. has released the Company's 3Q2023 unaudited condensed interim consolidated Financial Statements, showing a 13% decrease in total revenue and other significant financial highlights

Financial Statements Theralase Technologies Inc. Clinical Research 3Q2023 Revenue Decrease
COMMUNIQUÉ DE PRESSE

publié le 29/11/2023 à 22:35, il y a 11 mois 22 jours

Theralase(R) Closes $CAN 1.17 Million Non-Brokered Private Placement
COMMUNIQUÉ DE PRESSE

publié le 17/11/2023 à 22:30, il y a 1 année

Theralase(R) Commences Non-Brokered Private Placement and Termination of Previously Announced Financing
COMMUNIQUÉ DE PRESSE

publié le 23/10/2023 à 23:55, il y a 1 année

Theralase(R) Announces Brokered LIFE Financing
COMMUNIQUÉ DE PRESSE

publié le 23/10/2023 à 13:00, il y a 1 année

Theralase(R) Optimizes Phase II Bladder Cancer Clinical Study
COMMUNIQUÉ DE PRESSE

publié le 16/10/2023 à 13:00, il y a 1 année 1 mois

Theralase(R) Provides Update on Bladder Cancer Clinical Study
COMMUNIQUÉ DE PRESSE

publié le 05/10/2023 à 13:00, il y a 1 année 1 mois

Theralase(R) Files US Patent for Enhanced Immunotherapy

Les Echos

Publié le 21/11/2024 à 06:58, il y a 20 heures 32 minutes

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Publié le 21/11/2024 à 06:58, il y a 20 heures 32 minutes

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Publié le 21/11/2024 à 06:58, il y a 20 heures 32 minutes

Netto-actiefwaarde per aandeel stijgt in zes maanden met 9,4% tot EUR 55,6 dankzij aanhoudend sterke groeiprestaties van portefeuille
Publié le 20/11/2024 à 20:07, il y a 1 jour 7 heures

Entech : Nouveaux objectifs stratégiques à moyen-terme et Chiffre d’Affaires du 1er semestre 2024
Publié le 20/11/2024 à 19:20, il y a 1 jour 8 heures

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting

Voir tout LES ECHOS COMFI WIRE

Accesswire

Publié le 22/11/2024 à 00:00, il y a 3 heures 30 minutes

Gratomic Announces Company and Operational Update
Publié le 21/11/2024 à 22:05, il y a 5 heures 25 minutes

Protagonist Announces Nomination of PN-881, a Potential Best-in-Class Oral Peptide IL-17 Antagonist Development Candidate
Publié le 21/11/2024 à 21:50, il y a 5 heures 40 minutes

Seventy Ninth Resources Announces Successful First Reconnaissance at McKellar Copper-Zinc and Enable Gold Projects
Publié le 21/11/2024 à 20:15, il y a 7 heures 15 minutes

Woodland Park Zoo Awarded Transformative Grant to Advance Empathy for Animals
Publié le 21/11/2024 à 20:10, il y a 7 heures 20 minutes

For Us TV Productions, a Portfolio Company of Belle Bonica Luxe Corp., Invites BIPOC Filmmakers and Producers to Join Its Inclusive Streaming Platform

Voir tout ACCESSWIRE

EQS Group

Publié le 21/11/2024 à 19:01, il y a 8 heures 29 minutes

Fuller, Smith & Turner PLC: Transaction in own shares
Publié le 21/11/2024 à 18:36, il y a 8 heures 54 minutes

Original-Research: Beaconsmind AG (von First Berlin Equity Research GmbH): BUY
Publié le 21/11/2024 à 17:58, il y a 9 heures 31 minutes

Funding Circle Plc: POS-Transaction in Own Shares
Publié le 21/11/2024 à 17:51, il y a 9 heures 38 minutes

LIGHTON announces highly successful IPO on Euronext Growth Paris.
Publié le 21/11/2024 à 17:51, il y a 9 heures 38 minutes

LIGHTON annonce le vif succès de son introduction en Bourse sur Euronext Growth Paris.